← Back to Home
Obesity Pharmacotherapy Assistant
Evidence-based decision support for anti-obesity medication selection (AACE/ACE & AGA Guidelines).
1. Patient Anthropometrics & Mode Selection
Height (inches or cm)
Weight (lbs or kg)
Calculated BMI (kg/m²)
Patient Primary Preference / Constraint
Maximum Efficacy (Injectable or Oral)
Oral Medications Preferred Only
Cost-Sensitive / Uninsured ($10–$50/mo)
GLP-1/GIP Avoidance / Non-Qualifier / Shortage
Waist Circumference (Optional)
2. Comorbidities & Clinical Indications
Obstructive Sleep Apnea (OSA)
MASLD / MASH (Fatty Liver)
ASCVD / Post-MI / Stroke / PAD
Heart Failure (HFpEF)
Type 2 Diabetes / Prediabetes
Migraines / Frequent Headaches
Desires Smoking / Nicotine Cessation
Concurrent Depression / Anxiety
Cravings / Binge Eating Pattern
PCOS / Insulin Resistance
3. Safety & Contraindication Screen
Personal/Family History of MTC or MEN 2
Pregnant / Planning Pregnancy / Lactating
History of Seizures / Epilepsy / Abrupt Detox
Chronic Opioid Therapy / Methadone / Suboxone
Uncontrolled Hypertension (SBP >160 or DBP >100)
History of Eating Disorder (Anorexia/Bulimia)
History of Severe Acute Pancreatitis
GLP-1 Intolerance / Intolerable GI Side Effects
Evaluate Recommendations
All Options
GLP-1 / GIP Agents
Non-GLP-1 / Oral Alternatives
Medication Switches